Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance

21Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Healthcare delivery has advanced due to the implementation of point-of-care testing, which is often performed within minutes to hours in minimally equipped laboratories or at home. Technologic advances are leading to point-of-care kits that incorporate nucleic acid-based assays, including polymerase chain reaction, isothermal amplification, ligation, and hybridization reactions. As a limited number of single-nucleotide polymorphisms are associated with clinically significant human immunodeficiency virus (HIV) drug resistance, assays to detect these mutations have been developed. Early versions of these assays have been used in research. This review summarizes the principles underlying each assay and discusses strategic needs for their incorporation into the management of HIV infection.

Cite

CITATION STYLE

APA

Duarte, H. A., Panpradist, N., Beck, I. A., Lutz, B., Lai, J., Kanthula, R. M., … Frenkel, L. M. (2017). Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance. Journal of Infectious Diseases. Oxford University Press. https://doi.org/10.1093/infdis/jix413

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free